Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
The research interests of Petra Hirsova, Pharm.D., Ph.D., focus on understanding the pathogenic mechanisms of nonalcoholic fatty liver disease (NAFLD), a chronic hepatic manifestation of the metabolic syndrome. Dr. Hirsova's laboratory is specifically interested in the more progressive, inflammatory form of NAFLD termed nonalcoholic steatohepatitis (NASH).
The overall goal of Dr. Hirsova's research laboratory is to discover critical cellular and molecular processes underlying disease pathogenesis, which will ultimately guide the development of targeted therapies for patients with NASH. To this end, the lab utilizes biologically relevant mouse models, genetic and pharmacologic in vivo approaches, and state-of-the-art methodologies such as immunophenotyping by mass cytometry.
Increasingly common around the world, NAFLD is especially common in Western countries. In the U.S. it is the most common form of chronic liver disease affecting about one-quarter of the population. Dr. Hirsova's research has the potential to identify new approaches for fatty liver disease therapy that can be translated to patient care.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.